Cyclerion Therapeutics Inc (CYCN) Com Stk
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on to develop treatments for serious central nervous system (CNS) diseases through the discovery, development and commercialization of medicines. Its lead product, CY6463 (previously known as IW-6463), is a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator is in clinical development for Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv). CY6463 is an orally administered CNS-penetrant sGC stimulator that is being developed as a symptomatic and disease-modifying therapy for serious CNS diseases. CY6463 is the core of CNS portfolio with ongoing clinical programs in MELAS and ADv. It is focused on discovering new CNS-penetrant sGC stimulator(s). The Company also has clinical-phase sGC stimulators, praliciguat and olinciguat, and discovery and preclinical-phase compounds.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.